These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34489165)

  • 1. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid showing positive autoantibody responses to multiple epitopes.
    Kitao R; Fukumoto T; Hashimoto T; Izumi K; Jimbo H; Takemori C; Nishigori C
    J Dermatol Sci; 2021 Sep; 103(3):190-192. PubMed ID: 34489165
    [No Abstract]   [Full Text] [Related]  

  • 2. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
    Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
    J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    García-Díez I; España A; Iranzo P
    Br J Dermatol; 2019 May; 180(5):1267-1268. PubMed ID: 30675718
    [No Abstract]   [Full Text] [Related]  

  • 5. Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients.
    Mai Y; Nishie W; Izumi K; Yoshimoto N; Morita Y; Watanabe M; Toyonaga E; Ujiie H; Iwata H; Fujita Y; Nomura T; Sato-Matsumura KC; Shimizu S; Shimizu H
    Br J Dermatol; 2018 Sep; 179(3):790-791. PubMed ID: 29624639
    [No Abstract]   [Full Text] [Related]  

  • 6. Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading.
    Takama H; Yoshida M; Izumi K; Yanagishita T; Muto J; Ohshima Y; Nishie W; Shimizu H; Akiyama M; Watanabe D
    Acta Derm Venereol; 2018 Nov; 98(10):983-984. PubMed ID: 30085319
    [No Abstract]   [Full Text] [Related]  

  • 7. Βullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?
    Patsatsi A; Kyriakou A; Meltzanidou P; Trigoni A; Lamprou F; Kokolios M; Giannakou A
    Eur J Dermatol; 2018 Oct; 28(5):711-713. PubMed ID: 30325322
    [No Abstract]   [Full Text] [Related]  

  • 8. Regulatory T cell subsets in bullous pemphigoid and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    Muramatsu K; Zheng M; Yoshimoto N; Ito T; Ujiie I; Iwata H; Shimizu H; Ujiie H
    J Dermatol Sci; 2020 Oct; 100(1):23-30. PubMed ID: 32843228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis.
    Maki N; Nishie W; Takazawa M; Kakurai M; Yamada T; Umemoto N; Kawase M; Izumi K; Shimizu H; Demitsu T
    J Dermatol; 2018 May; 45(5):600-602. PubMed ID: 29446164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
    Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
    Am J Clin Dermatol; 2021 Jan; 22(1):117-127. PubMed ID: 33026629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab.
    Sato Y; Fujimura T; Mizuashi M; Aiba S
    J Dermatol; 2019 Oct; 46(10):e374-e375. PubMed ID: 31062404
    [No Abstract]   [Full Text] [Related]  

  • 12. Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
    Fania L; Salemme A; Provini A; Pagnanelli G; Collina MC; Abeni D; Didona B; Di Zenzo G; Mazzanti C
    J Am Acad Dermatol; 2018 Mar; 78(3):592-595. PubMed ID: 28987492
    [No Abstract]   [Full Text] [Related]  

  • 13. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
    Nishie W
    Immunol Med; 2019 Mar; 42(1):22-28. PubMed ID: 31169082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of anti-laminin γ1 (p200) pemphigoid developed after dipeptidyl peptidase-4 inhibitor administration.
    Nakatani K; Noborio R; Nomura Y; Ueki Y; Kiyohara T; Hashimoto T
    J Dermatol; 2024 Jun; 51(6):869-872. PubMed ID: 38214494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
    Hibi A; Kasahara Y; Ishihara Y; Hata K; Hosokawa N; Nakagawa T
    CEN Case Rep; 2020 Aug; 9(3):189-194. PubMed ID: 31993957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid.
    Izumi K; Nishie W; Mai Y; Wada M; Natsuga K; Ujiie H; Iwata H; Yamagami J; Shimizu H
    J Invest Dermatol; 2016 Nov; 136(11):2201-2210. PubMed ID: 27424319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
    Gaudin O; Seta V; Alexandre M; Bohelay G; Aucouturier F; Mignot-Grootenboer S; Ingen-Housz-Oro S; Bernardeschi C; Schneider P; Mellottee B; Caux F; Prost-Squarcioni C
    Front Immunol; 2018; 9():1030. PubMed ID: 29881377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
    García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
    Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of bullous pemphigoid with IgG antibodies against LAD-1, but not BP180 NC16a domain or BP230.
    Miyashita K; Iioka H; Miyagawa F; Ishii N; Hashimoto T; Asada H
    Eur J Dermatol; 2018 Apr; 28(2):248-250. PubMed ID: 29378676
    [No Abstract]   [Full Text] [Related]  

  • 20. A case of dipeptidyl peptidase-4 inhibitor-related anti-BP230-type bullous pemphigoid showing granular C3 dermatosis-like direct immunofluorescence staining.
    Hashimoto T; Tsunoda T; Arai Y; Izumi K; Ishii N; Qian H; Li X; Tsuruta D
    Eur J Dermatol; 2022 Jul; 32(4):549-551. PubMed ID: 36301770
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.